Warner Chilcott Hit With Suit Over IPO Prospectus

Law360, New York (November 2, 2006, 12:00 AM EST) -- Drug maker Warner Chilcott Ltd. deliberately failed to disclose that it had pulled one of its top earning drugs from shelves amid a federal antitrust investigation just days before its initial public offering, shareholders have alleged in a newly filed class action securities suit.

Filed by plaintiffs firm Lerach Coughlin Stoia Geller Rudman & Robbins in the U.S. District Court for the Southern District of New York, the complaint claims that Warner made misleading statements in its IPO prospectus, omitting details about a Federal Trade Commission...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.